Protagonist Therapeutics, Inc. (PTGX) earnings

  • Healthcare
  • NASDAQ
  • Market cap$7.9B

Next report

2027-02-24

In 95 daysQ4 FY2026Time not announced· Expected date
EPS consensus
-0.13
-0.17 – -0.085 analysts
Revenue consensus
$45.4M
Beat streak
2

Latest result

16 days ago

⁦+22.8%⁩EPS Beat

2026-11-05Q3 FY2026AMC
EPS
Reported / estimate3.07 / 2.50
Revenue
$274M / $238M⁦+15.1%⁩

Stock reaction

⁦-2.38%⁩

⁦-2.69⁩ pts vs SPY

Session ⁦2026-11-06⁩

Recent quarters

Latest 3 quarters

Revenue and stock reaction

Beat in 2 of 2 quarters with a measured stock reaction · beat then fell 1

Reported / estimate

  • Q3 FY2026 · 2026-11-05-2.38%
    EPS3.07 / 2.50+22.8%
    Revenue$274M / $238M+15.1%
  • Q2 FY2026 · 2026-08-05+6.45%
    EPS2.29 / 2.23+2.7%
    Revenue$213M / $199M+7.5%
  • Q1 FY2026 · 2026-05-05+4.80%
    EPS0.05 / -0.65+107.7%†
    Revenue$56.4M / $11.7M+381.7%
  • †Unusually large: likely a one-off gain or charge, so not comparable with consensus
  • Estimate recorded after the releaseNo estimate was saved before the results came out, so the surprise is measured against an estimate recorded after the release.

Reaction is the close of the reacting session versus the previous close. The gap to SPY is in percentage points.